Xanomeline/trospium chloride

Common card · No. 337297

Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. It contains xanomeline and trospium chloride, both of which are muscarinic antagonists. Xanomeline is a functionally-preferring muscarinic acetylcholine receptor M4 and M1 receptor agonist. Trospium chloride is a peripherally-acting non-selective muscarinic antagonist. The most common side effects of xanomeline/trospium chloride include nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia (increased heartbeat), dizziness, and gastroesophageal reflux. In September 2024, it was approved for medical use in the United States. It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. The FDA considers it to be a first-in-class medication. Trospium...

Read on Wikipedia · Image Vaccinationist, Public domain